Kilitch Drugs (India) Ltd

Kilitch Drugs maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating limited leverage and a strong equity base. The company holds INR 189.6 million in cash and equivalents, but its operating cash flow is negative at INR -1.46 million, suggesting operational cash generation is a challenge. The current ratio of 2.27 implies the company has sufficient short-term assets to cover its liabilities, but the negative net cash position after subtracting total debt raises liquidity concerns.

Profitability metrics show a return on equity (ROE) of 2.04% and a return on assets (ROA) of 1.5%, both below the industry median for pharmaceutical firms. The gross profit margin is 32.2%, which is in line with the sector average, but the operating margin of 13.7% is weak, indicating inefficiencies in cost control or pricing power. The net profit margin of 8.0% is also below the industry median, suggesting pressure on profitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond India. This lack of diversification increases exposure to domestic regulatory, economic, and currency risks. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or therapeutic areas.

Looking ahead, the company is expected to grow revenue by 5.3% in the current fiscal year and 4.1% in the next, based on analyst estimates. However, these growth rates are modest compared to the industry average of 8.2% and suggest limited expansion potential. The capital expenditure of INR -64.5 million indicates a reduction in investment, which may signal a strategic shift or financial constraints.

The risk assessment highlights medium liquidity risk due to the negative net cash position and weak operating cash flow. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of a pending equity raise. However, the negative operating cash flow and low profitability increase the risk of future dilution if the company requires capital to fund operations or growth initiatives.

Recent filings and transcripts do not indicate any major strategic changes or new product launches. The company's price target is uniformly set at INR 232.00 by analysts, with a mean recommendation of 2.00 (Buy). The lack of strong buy ratings suggests limited upside potential in the near term.

Revenue grew 14.8% CAGR over four years, demonstrating consistent top-line expansion for the pharmaceutical company.

Net income surged 38.0% CAGR over four years, significantly outpacing revenue growth and indicating strong profitability.

Net margin of 8.0% exceeds the 3.9% industry median, reflecting strong bottom-line performance relative to peers.

Analyst consensus suggests 56.8% upside to a target price of 232.0, indicating positive market sentiment.

Free cash flow turned negative at -188.2 million INR in the latest period, signaling potential liquidity pressures.

Long-term debt increased to 494.2 million INR in the latest period, raising concerns about leverage and solvency.

Cash conversion ratio of -0.04 is in the bottom quartile, suggesting poor ability to convert earnings to cash.

Medium liquidity and credit risk flags indicate potential challenges in meeting short-term obligations and debt servicing.

Revenue INR 1.54B, +10,6% YoY; Operating income +49,6% YoY.

• ▍Revenue INR 1.54B, +10,6% YoY
• ▍Operating income +49,6% YoY
• ▍Net income +39,8% YoY
• ▍Free cash flow +30,6% YoY
• ▍Net margin 9.5%

Revenue INR 1.40B, +22,2% YoY; Operating income +62,5% YoY.

• ▍Revenue INR 1.40B, +22,2% YoY
• ▍Operating income +62,5% YoY
• ▍Net income +41,8% YoY
• ▍Free cash flow +1 212,7% YoY
• ▍Net margin 7.5%

Revenue INR 1.14B, +66,7% YoY; Operating income +166,8% YoY.

• ▍Revenue INR 1.14B, +66,7% YoY
• ▍Operating income +166,8% YoY
• ▍Net income +100,7% YoY
• ▍Free cash flow +97,6% YoY
• ▍Net margin 6.4%